MiNK Therapeutics (NASDAQ:INKT) Price Target Raised to $35.00

MiNK Therapeutics (NASDAQ:INKT) had its price target increased by HC Wainwright from $9.00 to $35.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for MiNK Therapeutics’ Q1 2025 earnings at ($0.51) EPS, Q2 2025 earnings at ($0.27) EPS, Q3 2025 earnings at ($0.26) EPS, Q4 2025 earnings at ($0.29) EPS, FY2025 earnings at ($1.20) EPS, FY2026 earnings at ($0.77) EPS, FY2027 earnings at ($0.73) EPS, FY2028 earnings at ($0.45) EPS and FY2029 earnings at ($0.02) EPS.

Separately, Robert W. Baird dropped their price objective on shares of MiNK Therapeutics from $80.00 to $40.00 and set an “outperform” rating on the stock in a research note on Friday, November 15th.

MiNK Therapeutics Trading Down 0.6 %

Shares of INKT stock opened at $9.26 on Tuesday. The company’s fifty day moving average price is $8.55 and its 200-day moving average price is $7.75. The stock has a market cap of $36.69 million, a PE ratio of -2.37 and a beta of 0.17. MiNK Therapeutics has a 12 month low of $4.56 and a 12 month high of $19.00.

About MiNK Therapeutics

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.